Bayer
Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. As an innovation company, it sets trends in research-intensive areas. Bayer's products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2014, the Group employed 118,900 people and had sales of EUR 42.2 billion. Capital expenditures amounted to EUR 2.5 billion, R&D expenses to EUR 3.6 billion.
Business & Industry
- Pfizer and BioNTech to provide 500 million doses of COVID-19 vaccine to U.S. government for donation to poorest nations
- Valneva completes Phase 3 trial recruitment for its inactivated COVID-19 vaccine candidate
- Bayer to advance two first-of-its-kind cell and gene therapies for Parkinson's disease
- Pfizer and BioNTech receive first authorization in European Union for COVID-19 vaccine in adolescents
- Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19
Research & Development
- An omega-3 that's poison for tumors
- Common diabetes drug shows promise as treatment for COVID-19 lung inflammation
- CDC COVID-19 study shows mRNA vaccines reduce risk of infection by 91 percent for fully vaccinated people
- Protein identified as new therapeutic anti-viral target for COVID-19
- Monoclonal antibody prevents HIV infection in monkeys, study finds
- NIH researchers identify potential new antiviral drug for COVID-19
- How to obtain immune bovine milk to strengthen the body against COVID-19
Conferences & Events
- Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
- CPhI Worldwide to return in 2021
- Reuters Events' Cell & Gene Therapy USA
- Total health: Build a better healthcare system
- Don't fall for the 'next best action' trap
- Locking down shape-shifting spike protein aids development of COVID-19 vaccine
- COVID-19 vaccine innovation could dramatically speed up worldwide production
Regulatory Affairs
- FDA grants accelerated approval for Alzheimer's drug
- FDA approves new drug treatment for chronic weight management, first since 2014
- FDA authorizes additional monoclonal antibody for treatment of COVID-19
- FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in adolescents in another important action in fight against pandemic
- FDA and CDC lift recommended pause on Johnson & Johnson (Janssen) COVID-19 vaccine use following thorough safety review